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In  addition  to  +TIPs,  other  non-
classical MAPs are being identified. 
According  to  recent  studies  that 
analyzed microtubules in vivo using 
cryo-electron  tomography,  dense 
material  may  bind  to  the  inside  or 
become  part  of  microtubule  walls 
(Sui  and  Downing,  2006;  Nicas-
tro  et  al.,  2006;  Bouchet-Marquis 
et  al.,  2006).  The  actual  composi-
tion  of  this  dense  material  (which 
may  include new classes of MAPs) 
and its function are not fully under-
stood. Nonetheless,  it  is  becoming 
increasingly clear that microtubules 
provide  a  variety  of  diverse  inter-
faces  to MAPs. This might be evo-
lutionarily advantageous because a 
particular  mutation  of  tubulin  may 
favorably  change  its  interaction 
with  one  MAP  without  disturbing 
its  interactions  with  other  MAPs. 
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with stem cells?





There is currently no effective treatment for the devastating muscle-wasting disease 
Duchenne muscular dystrophy (DMD). Cossu and colleagues report in a recent Nature 
paper that transplantation of mesoangioblast stem cells may hold promise for treating 
DMD. Further studies are required to fully evaluate the clinical potential of these blood-
vessel-associated stem cells.Duchenne muscular dystrophy (DMD) 
is a devastating X-linked muscle dis-
ease  resulting  from  the  loss  of  the 
large  cytoskeletal  protein dystrophin. 
Affected  males  suffer  progressive 
muscle degeneration and typically die 
in  their  late  teens  or  early  twenties. 
No effective treatment is available but 
some therapeutic  interventions are  in 
clinical  trials,  including  viral  delivery 
of dystrophin and exon skipping using 
antisense oligonucleotides to replace 
defective  dystrophin  (Nowak  and 1304  Cell 127, December 29, 2006 ©2006Davies, 2004). A useful animal model 
of  DMD  is  the  golden  retriever  dog 
model  in  which  a  single  mutation  in 
intron 6 of the dystrophin gene results 
in  complete  absence  of  the  protein 
and  a  recapitulation  of  the  severe 
muscle  degeneration  and  pathology 
seen in human DMD patients.




tive  dystrophin  with  the  wild-type  Elsevier Inc.protein. In a recent study, Cossu and 
colleagues put this to the test deliver-
ing a blood-vessel-derived stem cell, 








from  the  skeletal muscle of  a  young 
healthy  unrelated  donor  dog  (heter-
ologous cells); others received mes-
oangioblasts that had been removed 
from  the  affected  dogs  (autologous 
cells)  and  transduced with  a  lentivi-
ral vector expressing human microd-
ystrophin, a  truncated but  functional 
version  of  dystrophin.  Either  heter-
ologous or autologous mesoangiob-





lasts  also  received  immunosuppres-
sant  drugs.  The  results  of  the  stem 
cell  injections  are  very  encouraging 
with improvements observed in mus-
cle  function and mobility  in  the dys-









The  use  of  embryonic  or  fetal-
derived  stem  cells  for  transplanta-
tion  purposes  raises  complex  ethi-
cal  issues,  whereas  obtaining  stem 
cells from postnatal and adult tissues 
avoids  many  of  these  difficulties. 
Mesoangioblasts  were  originally  iso-
lated  from  blood  vessels  of  the  dor-
sal  aorta  in  mouse  embryos  (Galvez 
et  al.,  2006).  In  the  dog  study,  the 






sels  and  surrounding  mesenchymal 
tissue  are  plated  in  culture  to  obtain 
these cells. Although the mesoangiob-
lasts  in  the  dog  study  were  derived 
from blood vessels in postnatal mus-
cle, it is difficult to formally exclude the 
possibility  that  they might  instead be 
derived  from  other  types  of  mesen-
chymal  tissue  with  known  myogenic 
potential, such as mesenchymal stem 
cells  or  muscle-derived  stem  cells 
(Lee-Pullen and Grounds, 2005). One 
way  to  overcome  possible  problems 
of  contamination  by  myogenic  stem 
cells would be to extract the mesoan-gioblasts  from blood vessels derived 
from  nonmuscle  tissues  (although 
ubiquitous  mesenchymal  stem  cells 
exist  here  too).  This  issue  does  not 
alter  the  value  of  dystrophin  restora-





The  specific  contribution  of  stem 
cells  to  the  improvements  in  the 
DMD  dogs  relies  largely  on  detect-
ing  stem  cell-derived  dystrophin 
within skeletal muscles of the treated 
animals,  in particular  the  leg muscle 
receiving  the  injection.  The  authors 
present detailed dystrophin analyses 
for four of the nine test animals (two 
injected  with  heterologous  mesoan-
gioblasts  and  two  with  autologous 
mesoangioblasts).  Although  dys-
trophin  expression  was  increased 
in  many  muscles,  there  was  not 
always  a  close  relationship between 
the  number  of  dystrophin-positive 
myofibers  and  the  overall  improve-
ments  observed  (Sampaolesi  et  al., 
2006).  The  proposal  that  replace-
ment  of  missing  dystrophin  was  a 
major  factor  in  the  improved  health 
of  the  treated  dogs—especially  for 
those  that  received  heterologous 
cells—requires further substantiation. 
One reason for the lesser benefits in 
dogs  injected  with  the  genetically 
corrected  autologous  cells  is  that, 
although  human  dystrophin  is  very 
similar to dog dystrophin, the human 
microdystrophin  introduced  into  the 
autologous  cells will  not  function  as 
well as  the  full-length native protein. 
Dystrophin analysis  in  the  remaining 
five treated dogs might help to clarify 
these issues.
There  may  be  other  explanations 
for the improved strength and gait of 
skeletal muscles and reduced serum 
creatine  kinase  levels  (an  indicator 
of  improved  muscle  health)  in  dogs 





tory  and  immunosuppressive  drugs 
can  reduce  the  severity  of muscular 
dystrophy (Radley et al., 2006). Early Cell 127, Decemclinical  trials  with  the  immunosup-
pressant  drug  cyclosporine  in  DMD 
patients  significantly  increased 
muscle  force  after  2  months  of 
treatment;  a  similar  effect  is  also 
seen  with  the  steroid  prednisolone 
(Sharma  et  al.,  1993).  A  long-term 
study  using  cyclosporine  combined 
with myoblast  therapy  to  treat  DMD 
patients attributed many of  the ben-
efits  of  increased  strength  after  7 
months to the effects of cyclosporine 
alone  (Miller  et  al.,  1997).  Currently, 





histological  evidence  of  myofiber 
damage, and dramatically decreased 
serum  creatine  kinase  levels,  along 
with  other  benefits  (De  Luca  et  al., 





The  dosage  and  impact  of  the 
drugs  used  in  this  dystrophic  dog 
model need to be carefully assessed. 
The  data  suggest  that  a  combined 
therapy of immunosuppressive drugs 
and  steroids  (received  by  the  dogs 




interest  in  such  potential  combined 
drug  therapies  for  treating  muscu-
lar  dystrophy  in  humans.  Treatment 
of  control  dogs  with  the  same  drug 
combinations  but  without  stem  cell 
injections  would  provide  vital  data 
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of  neurons  can  have  vastly  different 
axon and dendrite patterns. We now 
know  that  these  unique  axon/den-
drite  patterns  correspond  with  how 
a particular neuron fits  into a circuit. 
The  underlying  molecular  events 
governing  axon/dendrite  patterning 
in circuit formation are a major topic 
of  interest.  One  important  principle 
in  the  formation of neuronal circuits, 
which stems from the work of Victor 
Hamburger  and  his  contemporar-
ies,  is  that  the  amount  of  neuronal 
innervation  a  target  tissue  receives 
is  proportional  to  the  amount  of 
survival  factors  it  secretes  (Cowan, 
2001).  Since  this  revelation  over  50 
years  ago,  we  now  realize  that  tar-
get-derived growth  factors  influence 
survival,  axon  elaboration,  branch-
ing,  dendrite  growth,  circuit  assem-
Retrograde co
formation
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bly, and acquisition of neurotransmit-
ter  phenotype  (Frank  and  Wenner, 
1993;  Glebova  and  Ginty,  2005; 
Howe  and  Mobley,  2005).  However, 
the molecular mechanisms by which 
target-derived factors and retrograde 
signaling  regulate  these  processes 
remain  poorly  defined.  In  this  issue, 
Vrieseling  and  Arber  (2006)  provide 
exciting  new molecular  insights  into 
how  a  target-derived  growth  factor 
controls  neural  circuit  formation  in 
the developing spinal cord.
Sensory neurons of the dorsal root 
ganglia  are  unique  in  that  they  have 
an  axon  with  two  major  branches, 
one of which projects  to  the periph-
ery while  the  other  projects  into  the 
spinal  cord. Sensory  neurons  of  the 
dorsal  root  ganglia  that  monitor  the 
position  of  the  body  in  space  are 
referred to as proprioceptive neurons. 
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107, 299–310.controls the proprioceptive reflex, the 
central  branches  of  proprioceptive 
sensory axons connect either directly 
(making  one  synaptic  connection: 
monosynaptic)  or  indirectly  (making 
two  or  more  connections  through 
interneurons: polysynaptic) with den-
drites of motor neurons that innervate 
different  muscle  groups  (Chen  et 
al.,  2003).  Although  anatomical  and 
physiological characteristics of these 
reflex circuits have been defined, the 
molecular  and  genetic  determinants 
that  specify  the  formation  of  circuit 
architecture remain unknown.
At  the  outset  of  their  study,  the 
authors inject retrograde tracers into 
various  skeletal  muscle  groups  and 
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